Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging Abnormalities (EVOLVE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03639987
Recruitment Status : Terminated (Study was discontinued based on futility analysis conducted on Phase 3 trials (NCT02477800 and NCT02484547) and not based on safety concerns.)
First Posted : August 21, 2018
Last Update Posted : August 3, 2020
Sponsor:
Information provided by (Responsible Party):
Biogen

Results Submitted - Quality Control (QC) Review Has Not Concluded
Results information for an applicable clinical trial (ACT) is posted within 30 days of submission even if the submission has not completed the ClinicalTrials.gov Results Quality Control (QC) review process. Results information is submitted to ClinicalTrials.gov by the sponsor or investigator, and National Library of Medicine (NLM) staff assess for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.

All versions of ACT results information submissions that have not completed the QC review process are posted on ClinicalTrials.gov (since January 2020). After the QC review process is completed, the results information is posted without QC review comments and previous versions are archived.

Recruitment Status : Terminated
Actual Primary Completion Date : July 30, 2019
Actual Study Completion Date : July 30, 2019
Certification/Extension First Submitted : July 29, 2020
Submission Cycle Results Submitted to ClinicalTrials.gov Results Returned after Quality Control Review
1 July 6, 2021
July 27, 2021 Submission with QC Comments